Biotech Values

[DewDiligence]

(ENTA)—Japan’s Shionogi—>another player in COVID antivirals:

https://the-japan-news.com/news/article/0008075249

Pharmaceutical company Shionogi and Co. aims to have the oral COVID-19 drug it is currently developing used both at home and abroad, its president said during a recent interview with The Yomiuri Shimbun [the publication you are now reading].

President Isao Teshirogi also said the company will select its partners for clinical trials and production in foreign countries within this year. Trials of the drug on COVID-19 patients in North America and Europe are expected to start early next year.

…Shionogi is presently expediting its efforts for the final-stage clinical trial in Japan. As it is difficult to secure enough patients for trials due to a decline in the number of new infections in Japan, Shionogi plans to apply for approval following clinical trials in such countries as Singapore and South Korea, where the medical systems and people’s average weights are similar to Japan.

h/t @bio_clouseau.